Fol. Biol. 2020, 66, 7-16

https://doi.org/10.14712/fb2020066010007

Comprehensive Analysis of PTEN in Primary Cutaneous Melanoma

Kristýna Němejcová1, P. Dundr1, R. Jakša1, M. Bártů1, I. Stružinská1, J. Hojný1, N. Hájková1, O. Kodet2,3

1Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
2Department of Dermatology and Venereology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
3Institute of Anatomy, First Faculty of Medicine, Charles University, Czech Republic

Received September 2019
Accepted November 2019

References

1. Abbotts, R., Jewell, R., Nsengimana, J., Maloney, D. J., Simeonov, A., Seedhouse, C., Elliott, F., Laye, J., Walker, C., Jadhav, A., Grabowska, A., Ball, G., Patel, P. M., Newton- Bishop, J., Wilson, D. M., 3rd., Madhusudan, S. (2014) Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy. Oncotarget 5, 3273-3286. <https://doi.org/10.18632/oncotarget.1926>
2. Aguissa-Toure, A. H., Li, G. (2012) Genetic alterations of PTEN in human melanoma. Cell. Mol. Life Sci. 69, 1475-1491. <https://doi.org/10.1007/s00018-011-0878-0>
3. Brown, K., Yang, P., Salvador, D., Kulikauskas, R., Ruohola- Baker, H., Robitaille, A. M., Chien, A. J., Moon, R. T., Sherwood, V. (2017) WNT/β-catenin signaling regulates mitochondrial activity to alter the oncogenic potential of melanoma in a PTEN-dependent manner. Oncogene 36, 3119-3136. <https://doi.org/10.1038/onc.2016.450>
4. Bucheit, A. D., Chen, G., Siroy, A., Tetzlaff, M., Broaddus, R., Milton, D., Fox, P., Bassett, R., Hwu, P., Gershenwald, J. E., Lazar, A. J., Davies, M. A. (2014) Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin. Cancer Res. 20, 5527-5536. <https://doi.org/10.1158/1078-0432.CCR-14-1027>
5. Cancer Genome Atlas Nerwork (2015) Genomic classification of cutaneous melanoma. Cell 161, 1681-1696.
6. Ciuffreda, L., Di Sanza, C., Cesta Incani, U., Eramo, A., Desideri, M., Biagioni, F., Passeri, D., Falcone, I., Sette, G., Bergamo, P., Anichini, A., Sabapathy, K., McCubrey, J. A., Ricciardi, M. R., Tafuri, A., Blandino, G., Orlandi, A., De Maria, R., Cognetti, F., Del Bufalo, D., Milella, M. (2012) The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. J. Mol. Med. (Berl.) 90, 667-679. <https://doi.org/10.1007/s00109-011-0844-1>
7. Conde-Perez, A., Larue, L. (2012) PTEN and melanomagenesis. Future Oncol. 8, 1109-1120. <https://doi.org/10.2217/fon.12.106>
8. de Campos, E. C., da Fonseca, F. P., Zequ Sde, C., Guimaraes, G. C., Soares, F. A., Lopes, A. (2013) Analysis of PTEN gene by fluorescent in situ hybridization in renal cell carcinoma. Rev. Col. Bras. Cir. 40, 471-475. <https://doi.org/10.1590/S0100-69912013000600009>
9. de Unamuno Bustos, B., Murria Estal, R., Perez Simo, G., Simarro Farinos, J., Pujol Marco, C., Navarro Mira, M., Alegre de Miquel, V., Ballester Sanchez, R., Sabater Marco, V., Llavador Ros, M., Palanca Suela, S., Botella Estrada, R. (2018) Aberrant DNA methylation is associated with aggressive clinicopathological features and poor survival in cutaneous melanoma. Br. J. Dermatol. 179, 394-404.
10. Deichmann, M., Thome, M., Benner, A., Egner, U., Hartschuh, W., Naher, H. (2002) PTEN/MMAC1 expression in melanoma resection specimens. Br. J. Cancer 87, 1431-1436. <https://doi.org/10.1038/sj.bjc.6600653>
11. Dillon, L. M., Miller, T. W. (2014) Therapeutic targeting of cancers with loss of PTEN function. Curr. Drug Targets 15, 65-79. <https://doi.org/10.2174/1389450114666140106100909>
12. Freeman, D. J., Li, A. G., Wei, G., Li, H. H., Kertesz, N., Lesche, R., Whale, A. D., Martinez-Diaz, H., Rozengurt, N., Cardiff, R. D., Liu, X., Wu, H. (2003) PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 3, 117-130. <https://doi.org/10.1016/S1535-6108(03)00021-7>
13. García, J. M., Silva, J., Peña, C., Garcia, V., Rodríguez, R., Cruz, M. A., Cantos, B., Provencio, M., España, P., Bonilla, F. (2004) Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer 41, 117-124. <https://doi.org/10.1002/gcc.20062>
14. Giles, K. M., Rosenbaum, B. E., Berger, M., Izsak, A., Li, Y., Illa Bochaca, I., Vega-Saenz de Miera, E., Wang, J., Darvishian, F., Zhong, H., Osman, I. (2019) Revisiting the clinical and biologic relevance of partial PTEN loss in melanoma. J. Invest. Dermatol. 139, 430-438. <https://doi.org/10.1016/j.jid.2018.07.031>
15. Goel, V. K., Lazar, A. J., Warneke, C. L., Redston, M. S., Haluska, F. G. (2006) Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J. Invest. Dermatol. 126, 154-160. <https://doi.org/10.1038/sj.jid.5700026>
16. Guldberg, P., thor Straten, P., Birck, A., Ahrenkiel, V., Kirkin, A. F., Zeuthen, J. (1997) Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 57, 3660-3663.
17. Han, B., Mehra, R., Lonigro, R. J., Wang, L., Suleman, K., Menon, A., Palanisamy, N., Tomlins, S. A., Chinnaiyan, A. M., Shah, R. B. (2009) Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod. Pathol. 22, 1083-1093. <https://doi.org/10.1038/modpathol.2009.69>
18. Lahtz, C., Stranzenbach, R., Fiedler, E., Helmbold, P., Dammann, R. H. (2010) Methylation of PTEN as a prognostic factor in malignant melanoma of the skin. J. Invest. Dermatol. 130, 620-622. <https://doi.org/10.1038/jid.2009.226>
19. Leonardi, G. C., Falzone, L., Salemi, R., Zanghi, A., Spandidos, D. A., McCubrey, J. A., Candido, S., Libra, M. (2018) Cutaneous melanoma: from pathogenesis to therapy (Review). Int. J. Oncol. 52, 1071-1080.
20. Li, D. M., Sun, H. (1998) PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc. Natl. Acad. Sci. USA 95, 15406-15411. <https://doi.org/10.1073/pnas.95.26.15406>
21. Lotan, T. L., Heumann, A., Rico, S. D., Hicks, J., Lecksell, K., Koop, C., Sauter, G., Schlomm, T., Simon, R. (2017) PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort. Oncotarget 8, 65566-65576. <https://doi.org/10.18632/oncotarget.19217>
22. Maiques, O., Cuevas, D., Garcia Dios, D. A., Coenegrachts, L., Santacana, M., Velasco, A., Romero, M., Sonia, G., Lambrechts, D., Dolcet, X., Amant, F., Matias-Guiu, X. (2014) FISH analysis of PTEN in endometrial carcinoma. Comparison with SNP arrays and MLPA. Histopathology 65, 371-388. <https://doi.org/10.1111/his.12396>
23. Micevic, G., Theodosakis, N., Bosenberg, M. (2017) Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities. Clin. Epigenetics 9, 34. <https://doi.org/10.1186/s13148-017-0332-8>
24. Mikhail, M., Velazquez, E., Shapiro, R., Berman, R., Pavlick, A., Sorhaindo, L., Spira, J., Mir, C., Panageas, K. S., Polsky, D., Osman, I. (2005) PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. Clin. Cancer Res. 11, 5153-5157. <https://doi.org/10.1158/1078-0432.CCR-05-0397>
25. Milella, M., Falcone, I., Conciatori, F., Cesta Incani, U., Del Curatolo, A., Inzerilli, N., Nuzzo, C. M., Vaccaro, V., Vari, S., Cognetti, F., Ciuffreda, L. (2015) PTEN: multiple functions in human malignant tumors. Front. Oncol. 5, 24. <https://doi.org/10.3389/fonc.2015.00024>
26. Mirmohammadsadegh, A., Marini, A., Nambiar, S., Hassan, M., Tannapfel, A., Ruzicka, T., Hengge, U. R. (2006) Epigenetic silencing of the PTEN gene in melanoma. Cancer Res. 66, 6546-6552. <https://doi.org/10.1158/0008-5472.CAN-06-0384>
27. Naus, N. C., Zuidervaart, W., Rayman, N., Slater, R., van Drunen, E., Ksander, B., Luyten, . G. P., Klein, A. (2000) Mutation analysis of the PTEN gene in uveal melanoma cell lines. Int. J. Cancer 87, 151-153. <https://doi.org/10.1002/1097-0215(20000701)87:1<151::AID-IJC23>3.0.CO;2-1>
28. Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., Williams, L. J., Deng, W., Chen, G., Mbofung, R., Lazar, A. J., Torres-Cabala, C. A., Cooper, Z. A., Chen, P. L., Tieu, T. N., Spranger, S., Yu, X., Bernatchez, C., Forget, M. A., Haymaker, C., Amaria, R., McQuade, J. L., Glitza, I. C., Cascone, T., Li, H. S., Kwong, L. N., Heffernan, T. P., Hu, J., Bassett, R. L, Jr.., Bosenberg, M. W., Woodman, S. E., Overwijk, W. W., Lizee, G., Roszik, J., Gajewski, T. F., Wargo, J. A., Gershenwald, J. E., Radvanyi, L., Davies, M. A., Hwu, P. (2016) Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 6, 202-216. <https://doi.org/10.1158/2159-8290.CD-15-0283>
29. Picanco-Albuquerque, C. G., Morais, C. L., Carvalho, F. L., Peskoe, S. B., Hicks, J. L., Ludkovski, O., Vidotto, T., Fedor, H., Humphreys, E., Han, M., Platz, E. A., De Marzo, A. M., Berman, D. M., Lotan, T. L., Squire, J. A. (2016) In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading. Virchows Arch. 468, 607-617. <https://doi.org/10.1007/s00428-016-1904-2>
30. Poetsch, M., Dittberner, T., Woenckhaus, C. (2001) PTEN/ MMAC1 in malignant melanoma and its importance for tumor progression. Cancer Genet. Cytogenet. 125, 21-26. <https://doi.org/10.1016/S0165-4608(00)00353-8>
31. Poetsch, M., Woenckhaus, C., Dittberner, T., Pambor, M., Lorenz, G., Herrmann, F. H. (1998a) Differences in chromosomal aberrations between nodular and superficial spreading malignant melanoma detected by interphase cytogenetics. Lab. Invest. 78, 883-888.
32. Poetsch, M., Woenckhaus, C., Dittberner, T., Pambor, M., Lorenz, G., Herrmann, F. H. (1998b) An increased frequency of numerical chromosomal abnormalities and 1p36 deletions in isolated cells from paraffin sections of malignant melanomas by means of interphase cytogenetics. Cancer Genet. Cytogenet. 104, 146-152. <https://doi.org/10.1016/S0165-4608(97)00471-8>
33. Reddy, B. Y., Miller, D. M., Tsao, H. (2017) Somatic driver mutations in melanoma. Cancer 123, 2104-2117. <https://doi.org/10.1002/cncr.30593>
34. Roh, M. R., Gupta, S., Park, K. H., Chung, K. Y., Lauss, M., Flaherty, K. T., Jonsson, G., Rha, S. Y., Tsao, H. (2016) Promoter methylation of PTEN is a significant prognostic factor in melanoma survival. J. Invest. Dermatol. 136, 1002-1011. <https://doi.org/10.1016/j.jid.2016.01.024>
35. Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R. C., Moriceau, G., Chodon, T., Guo, R., Johnson, D. B., Dahlman, K. B., Kelley, M. C., Kefford, R. F., Chmielowski, B., Glaspy, J. A., Sosman, J. A., van Baren, N., Long, G. V., Ribas, A., Lo, R. S. (2014) Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 4, 80-93. <https://doi.org/10.1158/2159-8290.CD-13-0642>
36. Sobin, L. H., Gospodarowicz, M. K., Wittekind, C., International Union against Cancer. (2010) TNM Classification of Malignant Tumours. Chichester, West Sussex, UK ; Hoboken, NJ, Wiley-Blackwell.
37. Song, M. S., Salmena, L., Pandolfi, P. P. (2012) The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 13, 283-296. <https://doi.org/10.1038/nrm3330>
38. Troyer, D. A., Jamaspishvili, T., Wei, W., Feng, Z., Good, J., Hawley, S., Fazli, L., McKenney, J. K., Simko, J., Hurtado- Coll, A., Carroll, P. R., Gleave, M., Lance, R., Lin, D. W., Nelson, P. S., Thompson, I. M., True, L. D., Brooks, J. D., Squire, J. A. (2015) A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate 75, 1206-1215. <https://doi.org/10.1002/pros.23003>
39. Whiteman, D. C., Zhou, X. P., Cummings, M. C., Pavey, S., Hayward, N. K., Eng, C. (2002) Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. Int. J. Cancer 99, 63-67. <https://doi.org/10.1002/ijc.10294>
40. Zhou, X. P., Gimm, O., Hampel, H., Niemann, T., Walker, M. J., Eng, C. (2000) Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am. J. Pathol. 157, 1123-1128. <https://doi.org/10.1016/S0002-9440(10)64627-5>
front cover

ISSN 0015-5500 (Print) ISSN 2533-7602 (Online)

Open access journal

Archive